{
    "Trade/Device Name(s)": [
        "CAPI 3 HEMOGLOBIN(E)"
    ],
    "Submitter Information": "Sebia, Inc.",
    "510(k) Number": "K180762",
    "Predicate Device Reference 510(k) Number(s)": [
        "K112550"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GKA"
    ],
    "Summary Letter Date": "December 14, 2018",
    "Summary Letter Received Date": "March 23, 2018",
    "Submission Date": "March 23, 2018",
    "Regulation Number(s)": [
        "21 CFR 864.7415"
    ],
    "Regulation Name(s)": [
        "Abnormal hemoglobin assay"
    ],
    "Analyte Class(es)": [
        "hematology"
    ],
    "Analyte(s)": [
        "Hemoglobin A",
        "Hemoglobin A2",
        "Hemoglobin F",
        "Hemoglobin S",
        "Hemoglobin C",
        "Hemoglobin E",
        "Hemoglobin D"
    ],
    "Specimen Type(s)": [
        "Venous human whole blood"
    ],
    "Specimen Container(s)": [
        "K2EDTA tube",
        "K3EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "SEBIA CAPILLARYS 3 TERA instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Capillary electrophoresis"
    ],
    "Methodologies": [
        "Hemoglobin fractionation"
    ],
    "Submission Type(s)": [
        "Kit",
        "Analyzer",
        "Reagent",
        "Consumable"
    ],
    "Document Summary": "FDA 510(k) summary for Sebia CAPI 3 HEMOGLOBIN(E) kit using capillary electrophoresis for quantitative analysis of normal and variant hemoglobin fractions in whole blood.",
    "Indications for Use Summary": "Separation and quantitation of normal hemoglobins (A, A2, F) and detection of major variants (S, C, E, D) in human venous whole blood using capillary electrophoresis on SEBIA CAPILLARYS 3 TERA instrument, for in vitro diagnostic use, in conjunction with other laboratory and clinical findings.",
    "fda_folder": "Hematology"
}